Proteome analysis of human androgen-independent prostate cancer cell lines: Variable metastatic potentials correlated with vimentin expression

被引:52
|
作者
Wu, Mingfu
Bai, Xiangyang
Xu, Gang
Wei, Juncheng
Zhu, Tao
Zhang, Yongtao
Li, Qiong
Liu, Ping
Song, Anping
Zhao, Liangpin
Gang, Chen
Han, Zhiqiang
Wang, Shixuan
Zhou, Jianfeng
Lu, Yunpin
Ma, Ding
机构
[1] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Canc Biol Res Ctr, Wuhan 430030, Hebei, Peoples R China
[2] Huazhong Univ Sci & Technol, Tongji Med Coll, Dept Pathol, Wuhan 430030, Hebei, Peoples R China
关键词
2-DE; androgen-independent prostate cancer; metastasis; vimentin;
D O I
10.1002/pmic.200600643
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
To better understand the molecular mechanisms of prostate cancer (PCA) dissemination and to develop new anti-metastasis therapies, key regulatory molecules involved in PCA metastasis were identified in two human androgen-independent PCA cell lines, highly metastatic 1E8-H and lowly metastatic 2B4-L, cells. Through 2-DE and MS analyses, 12 proteins with different expression levels in the two cell lines were identified. The following proteins were found to be significantly up-regulated in 1E8-H cells compared with 2B4-L cells: gp96 precursor, calreticulin precursor, vimentin (VIM), Hsp90 alpha, peroxiredoxin 2, HNRPH1, ezrin, T-complex protein 1, alpha subunit, and hypothetical protein mln2339. In contrast, heart L-lactate dehydrogenase H chain, annexin I, and protein disulfide isomerase were notably down-regulated in 1E8-H cells compared with 2B4-L cells. To our knowledge, this study is the first to demonstrate that up-regulation of VIM expression positively correlates with the invasion and metastasis of androgen-independent PCA.
引用
收藏
页码:1973 / 1983
页数:11
相关论文
共 50 条
  • [41] IMMUNOHISTOCHEMICAL EXPRESSION ANALYSIS OF POTENTIAL MOLECULAR TARGETS FOR THE MANAGEMENT OF ANDROGEN-INDEPENDENT PROSTATE CANCER
    Ohlmann, C-H.
    Markert, E.
    Dienes, H-P.
    Stoeckle, M.
    Engelmann, U.
    Heidenreich, A.
    EUROPEAN UROLOGY SUPPLEMENTS, 2009, 8 (04) : 296 - 296
  • [42] MicroRNA expression in androgen independent and metastatic prostate cancer
    Basturk, O.
    Wei, J.
    Kong, X.
    Zou, X.
    Peng, Y.
    Melamed, J.
    Lee, P.
    MODERN PATHOLOGY, 2008, 21 : 148A - 148A
  • [43] Racial disparity in clinical course and outcome of metastatic androgen-independent prostate cancer
    Thatai, LC
    Banerjee, M
    Lai, ZS
    Vaishampayan, U
    UROLOGY, 2004, 64 (04) : 738 - 743
  • [44] MicroRNA expression in androgen independent and metastatic prostate cancer
    Basturk, O.
    Wei, J.
    Kong, X.
    Zou, X.
    Peng, Y.
    Melamed, J.
    Lee, P.
    LABORATORY INVESTIGATION, 2008, 88 : 148A - 148A
  • [45] An active regimen of weekly paclitaxel and estramustine in metastatic androgen-independent prostate cancer
    Vaishampayan, U
    Fontana, J
    Du, W
    Hussain, M
    UROLOGY, 2002, 60 (06) : 1050 - 1054
  • [46] IL-22 Increases Metastatic Properties in Androgen-Independent Prostate Cancer
    Shafran, Jordan
    Andrieu, Guillaume
    Denis, Gerald V.
    JOURNAL OF IMMUNOLOGY, 2017, 198 (01):
  • [47] High-dose calcitriol and carboplatin in metastatic androgen-independent prostate cancer
    Beer, TM
    Garzotto, M
    Katovic, NM
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2004, 27 (05): : 535 - 541
  • [48] Docetaxel, estramustine, plus trastuzumab in patients with metastatic androgen-independent prostate cancer
    Small, EJ
    Bok, R
    Reese, DM
    Sudilovsky, D
    Frohlich, M
    SEMINARS IN ONCOLOGY, 2001, 28 (04) : 71 - 76
  • [49] Sipuleucel-T: A vaccine for metastatic, asymptomatic, androgen-independent prostate cancer
    Patel, Punam H.
    Kockler, Denise R.
    ANNALS OF PHARMACOTHERAPY, 2008, 42 (01) : 91 - 98
  • [50] Vinorelbine and estramustine in androgen-independent metastatic prostate cancer - A phase II study
    Smith, MR
    Kaufman, D
    Oh, W
    Guerin, K
    Seiden, M
    Makatsoris, T
    Manola, J
    Kantoff, PW
    CANCER, 2000, 89 (08) : 1824 - 1828